AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform. The deal will see AstraZeneca scoop up all ...

Eneboparatide hits primary endpoint in AstraZeneca’s Phase 3 trial for chronic hypoparathyroidism, showing significant efficacy at 24 weeks. The EU approved AstraZeneca’s Imfinzi for limited ...

AstraZeneca has announced two separate deals that will see the company acquire EsoBiotec for up to $1 billion as well as a licensing deal with Alteogen that will expand its work in oncology and cell ...

AstraZeneca bought Belgian biotech company EsoBiotec in a deal valued at up to $1 billion, to expand its cell-therapy portfolio. The British pharma company said Monday that it will pay $425 ...

AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. The injectable drug will serve as an official partner of the Professional ...

AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim analysis. The trial hit on progression-free survival (PFS), its ...

Read Our Latest Stock Report on AZN AstraZeneca Stock Down 0.3 % Shares of NASDAQ:AZN opened at $77.37 on Tuesday. The company has a market capitalization of $239.94 billion, a PE ratio of 34.23 ...

Feb 20 (Reuters) - AstraZeneca (AZN.L), opens new tab will buy longtime partner FibroGen's (FGEN.O), opens new tab China unit for about $160 million to gain rights to its anemia drug in the ...

Camizestrant combination improves progression-free survival Trial to continue as planned after interim analysis Results "material positive surprise," say Barclays analysts Feb 26 (Reuters ...

AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in early-stage stomach cancer met its main goal. When added to a ...

In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other high growth mega cap stocks. Exactly 5 years ago, the world struggled to deal with a ...